NASDAQ$XWEL

XpresSpa Group Inc · Q2 2020 earnings

Q2 2020 earnings · · Investor relations

Briefing

XpresSpa Group's financial results for Q2 2020 were filed, with a focus on the launch and expansion of XpresCheck testing facilities amidst the COVID-19 pandemic and the temporary closure of traditional spa locations.

XpresSpa Group announced its Q2 2020 financial results, highlighting the launch of XpresCheck COVID-19 testing facilities at JFK and Newark airports. The company temporarily closed all global spa locations due to COVID-19 restrictions and is focusing on expanding its health and wellness services through XpresCheck.

  • All global spa locations were temporarily closed starting March 24, 2020, due to COVID-19 restrictions.
  • The company launched XpresCheck COVID-19 testing facilities at JFK International Airport and Newark Liberty International Airport.
  • XpresSpa Group is in discussions with other airports to open new testing centers or convert existing spas to XpresCheck locations.
  • The company raised approximately $38.4 million through registered direct equity offerings to improve its working capital position.

Headline financials

Total Revenue

$143K

Previous: $12.9M-98.9%
EPS (adj)

-$1.40

Previous: -$7.53+81.4%
Capital Expenditures

-$1.35M

Previous: -$802K-67.7%
Free Cash Flow

-$59.4M

Previous: -$7.14M-732.3%
Net Income

-$58.1M

Previous: -$6.34M-816.3%
Operating Income

-$9.48M

Previous: -$1.85M-412.6%
Gross Profit

-$835K

Previous: $3.06M-127.3%
Cash & Equivalents

$37.8M

Previous: $2.26M+1571.8%
Total Assets

$58.2M

Previous: $33.3M+74.8%
Stock-Based Comp

$424K

No prior period

Revenue & EPS history

XpresSpa · Revenue · Quarterly

$143K

Q2 2020-98.9%vs Q2 2019
Beat estimate in 5 of 9 quarters(56%)
ActualEstimate

Revenue by segment

XpresSpa · $6.64M total across 3 segments · Q1 2026

  • XpresSpa
    $4.2M
  • XpresTest
    $1.92M
  • Naples Wax
    $524K

Forward guidance

XpresSpa Group is focused on expanding the XpresCheck concept across U.S. airports and into additional health and wellness services, while also managing the risks and regulatory challenges associated with the COVID-19 testing business.

Tailwinds

  • Expansion of XpresCheck concept across U.S. airports.
  • Potential to expand testing to other communicable diseases.
  • Opportunity to administer vaccinations for the seasonal flu.
  • Positioned to be part of the national rollout of a COVID-19 vaccination when available.
  • Focus on building comprehensive health and wellness service capabilities.

Headwinds

  • Risks and uncertainties related to domestic and international air travel due to COVID-19.
  • Regulatory challenges associated with the COVID-19 testing business.
  • Uncertainty regarding the timing of possible XpresCheck openings.
  • Dependence on airport traffic and passenger volume.
  • Potential for actual results to vary materially from expectations.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q2 2020

Historical avgQ2 2020

+1.1%

Avg return

Earnings day

-2.3%

Avg return

5 days after

-4.5%

Avg return

30 days after

43%

16 / 37 earnings

Positive

+24.4%

Q4 2019

Best reaction

-11.1%

Q4 2017

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026
Q3 2025+0.0%-8.4%-9.6%
Q2 2025-5.8%-8.3%-8.3%
Q1 2025+1.2%+12.8%+9.3%
Q4 2024+0.0%+0.0%+15.4%
Q3 2024-1.2%-10.6%-24.1%
Q2 2024+3.7%+0.5%-14.8%
Q1 2024+3.4%-8.4%+41.6%
Q4 2023+0.0%+0.7%+32.1%
Q3 2023+6.2%+35.4%+31.1%
Q2 2023-4.2%-4.2%-25.0%
Q1 2023+0.0%+4.2%+4.2%
Q4 2022+6.3%-9.4%-21.9%
Q3 2022+0.0%-12.3%-10.5%
Q2 2022-6.5%-5.4%+9.7%
Q1 2022-1.1%-18.7%-22.0%
Q4 2021+8.2%+52.0%+11.2%
Q3 2021+11.7%+13.1%+25.5%
Q2 2021-6.9%-13.1%-2.9%
Q4 2020+6.4%-3.5%-20.8%
Q3 2020-1.1%-13.4%-22.5%
Q2 2020-6.5%-4.2%-42.9%
Q1 2020-7.5%-5.5%+6.5%
Q4 2019+24.4%+26.8%+17.1%
Q3 2019+2.0%-5.9%-41.6%
Q2 2019+0.0%+21.2%+31.9%
Q1 2019+7.8%-9.0%-40.0%
Q4 2018+0.3%-12.0%-22.7%
Q3 2018+0.0%+0.0%+11.1%
Q2 2018+0.0%-25.0%-20.0%
Q1 2018-4.8%-31.7%-20.6%
Q4 2017-11.1%-24.7%-17.3%
Q3 2017-0.8%-4.0%-6.5%
Q2 2017+11.5%+4.4%+9.7%
Q1 2017+4.9%+1.9%+5.6%
Q4 2016+0.9%-9.7%-20.8%
Q3 2016+0.8%-8.0%-15.6%
Q2 2016-1.9%-1.0%+1.9%
Q1 2016
Q4 2015
Q3 2015
Q2 2015
Q1 2015
Q4 2014
Q3 2014
Q2 2014
Q1 2014
Q4 2013
Q3 2013
Q2 2013
Q1 2013
Q4 2012
Q3 2012
Q2 2012
Q1 2012
Q4 2011
Q3 2011

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro